Kolexia
Mortier Laurent Dermatologie
Mortier Laurent
Dermatologie
Hôpital Huriez
Lille, France
674 Activités
671 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Mélanome Tumeurs cutanées Carcinomes Carcinome basocellulaire Métastase tumorale Carcinome épidermoïde Carcinome à cellules de Merkel Kératose Kératose actinique

Collaborateurs

Voir plus
Lebbe Celeste
Lebbe Celeste
Hôpital Saint-Louis, Paris, France
Dutriaux Caroline
Dutriaux Caroline
Hôpital Saint-André, Bordeaux, France
Saiag Philippe
Saiag Philippe
Hôpital Ambroise Paré, Boulogne-Billancourt, France
Dalac Sophie
Dalac Sophie
Hôpital François Mitterrand, Dijon, France

Industries

Voir plus
Novartis
25 collaboration(s)
Dernière en 2023
A+A
18 collaboration(s)
Dernière en 2023
BMS
17 collaboration(s)
Dernière en 2023
IQVIA
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors: Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
Essai Clinique (IO Biotech)   15 mars 2024
Sequential combination of Sonic Hedgehog inhibitors followed by consolidation radiotherapy in locally advanced basal cell carcinoma.
Clinical and experimental dermatology   05 mars 2024
RELATIVITY-127: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Essai Clinique (BMS)   29 février 2024
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200): A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Essai Clinique (Emd Serono)   14 février 2024
Pan Tumor Nivolumab Rollover Study: Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Essai Clinique (BMS)   14 février 2024
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).: A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)
Essai Clinique (Anaveon AG)   09 février 2024
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Melanoma research   07 février 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Annales de dermatologie et de venereologie   06 février 2024
Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.
European journal of cancer (Oxford, England : 1990)   24 janvier 2024
CheckMate 238: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Essai Clinique (BMS)   05 janvier 2024